Alvotech has announced a new marketing agreement for its biosimilar of Cimzia, which applies to commercialization in Europe. The company has extended its marketing relationship with Advanz Pharma to include AVT10 in Europe. The US marketing of AVT10 (formally known as XB003) is still an open question. As reported in 2020, biosimilar manufacturers have in … Continue reading A Cimzia Biosimilar Update, and Another Ustekinumab Price Cut